Synlogic (NASDAQ:SYBX) Price Target & New Coverage by Piper Jaffray
Piper Jaffray has started its coverage on Synlogic (NASDAQ:SYBX), today 29 January. The financial firm finds the stock of SYBX attractive and has target price of $16.0 with Overweight rating.
After the coverage NASDAQ:SYBX is at the moment trading -3.36% lower at $18.10 as of 10:05 AM New York time. Synlogic’s stock is 0% over the past 200 days. It has underperformed the S&P 500, which has added 6.00% over the same time.
Synlogic (NASDAQ:SYBX) Profile
Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
Synlogic (NASDAQ:SYBX) traded down -3.36% on 29 January, hitting $18.1. A total of 4,681 shares of the company’s stock traded hands. This is down from average of 5,489 shares. Synlogic has a 52 week low of $7.84 and a 52 week high of $23. The company has a market cap of $294.71 million and a P/E ratio of 0.
Get the latest Synlogic (NASDAQ:SYBX) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Synlogic (NASDAQ:SYBX) Now Covered by Piper Jaffray. The Stock has $16.0 TP appeared first on Octafinance.